Anti-adhesion molecule therapy for inflammatory bowel disease
about
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's diseaseReview article: anti-adhesion therapies for inflammatory bowel diseaseUltrasound-based molecular imaging and specific gene delivery to mesenteric vasculature by endothelial adhesion molecule targeted microbubbles in a mouse model of Crohn's disease.Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United StatesVedolizumab for Crohn's disease.The Role of the Mesentery in Crohn's Disease: The Contributions of Nerves, Vessels, Lymphatics, and Fat to the Pathogenesis and Disease Course.Current and emerging drugs for the treatment of inflammatory bowel disease.Immune markers and differential signaling networks in ulcerative colitis and Crohn's diseaseMobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.Molecular imaging of inflammation in inflammatory bowel disease with a clinically translatable dual-selectin-targeted US contrast agent: comparison with FDG PET/CT in a mouse model.Angelica acutiloba Kitagawa Extract Attenuates DSS-Induced Murine Colitis.NSAIDs: learning new tricks from old drugsPharmacotherapy and management strategies for coeliac disease.Biologic therapies: lessons from multiple sclerosis.Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.Immunosuppressive and biologic therapy for ulcerative colitis.New therapeutic avenues in ulcerative colitis: thinking out of the box.Implication of miRNAs for inflammatory bowel disease treatment: Systematic review.Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?Tumor Necrosis Factor-Alpha Up-Regulates ICAM-1 Expression and Release in Intestinal Myofibroblasts by Redox-Dependent and -Independent Mechanisms.Alicaforsen: An Emerging Therapeutic Agent for Ulcerative Colitis and Refractory Pouchitis.Red wine polyphenolics reduce the expression of inflammation markers in human colon-derived CCD-18Co myofibroblast cells: potential role of microRNA-126.Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation.Altered generation of induced regulatory T cells in the FVB.mdr1a-/- mouse model of colitis.Gelatin tannate reduces the proinflammatory effects of lipopolysaccharide in human intestinal epithelial cells.Immunoregulatory function of PIR-A/B+ DCs in the inflammatory responses of dextran sodium sulfate-induced colitis.Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis.The effects of tacrolimus on colonic anastomotic healing in rats.An experimental study to evaluate safety/toxicity of intravitreal natalizumab
P2860
Q26786018-82A9B24D-5704-4C84-BC23-0A16738F15ECQ26999705-49022042-85FC-46E5-BFFE-C236165A404BQ30414837-7EA41CA5-C5ED-4712-9386-3F1691CAABA6Q33584629-21D01831-5755-4E41-BCEA-9274F32B6937Q34326912-3DE6A304-6C5D-4178-A6DB-DD5A7AF94E36Q34526079-48D093F8-E5E1-41EB-8C89-E9D4A07B4C40Q34883210-D2CFBE90-7C1C-4355-ADD7-C262F28E59ADQ36125752-D8396F11-FF7D-4042-B74E-BFB06A52FC9CQ36445393-90B7B4C7-3C49-46BE-B481-79E46841618AQ36871846-FE9EB072-5C4A-4B87-B840-DE3770D80F5CQ36949171-ACA33CEB-B28B-4E6C-8999-A88CED2E7522Q37341156-9C6A8C29-3DEC-4BCF-BEAB-45C47A09EABAQ37896092-92EBB0DC-957C-44AE-A485-5F95F4799751Q38026399-E686A39A-3B3C-42FD-9C95-55A0904A8F33Q38053495-BCCE394A-DB38-45EC-957C-EE11B0CFA0E1Q38060831-E2DCD3EE-6D43-4969-A2F6-296B29AD716DQ38150670-09A36A21-9FF0-45AF-86E4-50F550DCCCF6Q38217235-20A8490E-433E-439F-ADA6-4EB226F92753Q38217832-CBD992FA-10E9-4120-91DA-86154CE60D77Q38852709-D4E29ED9-615E-46AC-BE85-F69CAF1FD823Q38992068-753B47FC-76AE-4FAC-82A2-ED2D1EA6CB04Q39351291-1BAE6014-8540-4320-800F-9B4522D04A80Q41928163-FAE228E4-9913-4536-BD31-CB60537F857BQ42146204-EE8284CA-F3B9-4F95-9897-D31CA70B673BQ42176677-6E8D0EDB-1493-4AE7-ADF7-3E83901D78C5Q44126280-9DFF24CA-FE4D-4BD6-BD46-819653479B29Q46861949-84C635A4-22BD-4C50-A09B-34A0B2A5A780Q49130305-E8DA3203-6D50-4527-990C-5E1750E2F603Q53207525-A2136CA8-0554-42B6-ACC1-CB05028E367FQ58792660-2E8F3B4E-1943-454A-96C7-7E5243B1C06A
P2860
Anti-adhesion molecule therapy for inflammatory bowel disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-adhesion molecule therapy for inflammatory bowel disease
@en
Anti-adhesion molecule therapy for inflammatory bowel disease.
@nl
type
label
Anti-adhesion molecule therapy for inflammatory bowel disease
@en
Anti-adhesion molecule therapy for inflammatory bowel disease.
@nl
prefLabel
Anti-adhesion molecule therapy for inflammatory bowel disease
@en
Anti-adhesion molecule therapy for inflammatory bowel disease.
@nl
P2860
P356
P1476
Anti-adhesion molecule therapy for inflammatory bowel disease
@en
P2093
Remo Panaccione
Subrata Ghosh
P2860
P304
P356
10.1177/1756283X10373176
P577
2010-07-01T00:00:00Z